Results presented at EASL in April on combinations of GS7977 and...

Results presented at EASL in April on combinations of GS7977 and daclatasvir show that these 2 can achieve 100% SVR even in genotype 1 with 12 weeks treatment. Talking with 2 of Australasia's top researchers last week, they were confident of a protease/polymerase inhibitor combination with pan-genotypic efficacy being put before Australian regulatory authorities for approval early 2015. The presence of HIV should not actually affect the efficacy of these drugs, so there is no need to include a drug that acts on both - you just eradicate the HCV with HCV drugs, and manage HIV with HIV drugs.